| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Masayuki Koizumi, Ryuichiro Doi, Koji Fujimoto, Daisuke Ito, Eiji Toyoda, Tomohiko Mori, Kazuhiro Kami, Yoshiya Kawaguchi, George K Gittes, Masayuki Imamur. Pancreatic epithelial cells can be converted into insulin-producing cells by GLP-1 in conjunction with virus-mediated gene transfer of pdx-1. Surgery. vol 138. issue 2. 2005-10-18. PMID:16153418. |
glucagonlike peptide-1 (glp-1) stimulates insulin secretion and proliferation by islet cells in vitro and in vivo, associated with an activation of pancreatic duodenal homeobox gene-1 (pdx-1) function. |
2005-10-18 |
2023-08-12 |
Not clear |
| Hongxiang Hui, Xiaoning Zhao, Riccardo Perfett. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes/metabolism research and reviews. vol 21. issue 4. 2005-10-04. PMID:15852457. |
the multifaceted actions of glp-1 include the following: (1) the stimulation of insulin secretion and of its gene expression, (2) the inhibition of glucagon secretion, (3) the inhibition of food intake, (4) the proliferation and differentiation of beta cells, and (5) the protection of beta-cells from apoptosis. |
2005-10-04 |
2023-08-12 |
Not clear |
| Mark F McCart. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Medical hypotheses. vol 64. issue 4. 2005-09-27. PMID:15694706. |
the increased production of glp-1 associated with frequent coffee consumption could thus be expected to counteract the adverse impact of chronic free fatty acid overexposure on beta cell function in overweight insulin resistant subjects. |
2005-09-27 |
2023-08-12 |
human |
| Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederso. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochimica et biophysica acta. vol 1751. issue 1. 2005-09-27. PMID:15978877. |
it was published in 1996 for the first time that a specific dp iv inhibitor in a given dose was able to completely block glucagon-like peptide-1 (glp-1) degradation in vivo resulting in improved insulin response accompanied, by accelerated peripheral glucose disposal. |
2005-09-27 |
2023-08-12 |
rat |
| Ewa Bojanowsk. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Medical science monitor : international medical journal of experimental and clinical research. vol 11. issue 8. 2005-09-23. PMID:16049395. |
peripherally secreted glp-1 enhances insulin synthesis and release and maintains the normal anatomical status of pancreatic islets. |
2005-09-23 |
2023-08-12 |
human |
| Ewa Bojanowsk. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Medical science monitor : international medical journal of experimental and clinical research. vol 11. issue 8. 2005-09-23. PMID:16049395. |
diminished glp-1 response to ingested food, associated with attenuated insulin release and glucose intolerance, was found in non-insulin-dependent diabetes mellitus. |
2005-09-23 |
2023-08-12 |
human |
| Kwang-Rok Kim, Sang-Dal Rhee, Hee Youn Kim, Won Hoon Jung, Sung-Don Yang, Sung Soo Kim, Jin Hee Ahn, Hyae Gyeong Cheo. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. European journal of pharmacology. vol 518. issue 1. 2005-09-23. PMID:16106524. |
administration of kr-62436 to c57bl/6j mice either orally or subcutaneously resulted in the suppression of plasma dpp-iv activity, increase in intact glp-1 and insulin levels in plasma. |
2005-09-23 |
2023-08-12 |
mouse |
| Eugenio D'Amico, Hongxiang Hui, Nasif Khoury, Umberto Di Mario, Riccardo Perfett. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. Journal of molecular endocrinology. vol 34. issue 2. 2005-09-22. PMID:15821104. |
finally, to study whether the antiapoptotic action of glp-1 was a function of its effect on insulin secretion, or rather it was a direct effect of glp-1, cells were cultured with or without diazoxide or exendin-9. |
2005-09-22 |
2023-08-12 |
mouse |
| L Bai, G Meredith, B E Tuc. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079260. |
addition of glp-1 (100 nm) and nicotinamide (10 mm) at stage 5 resulted in a 50% and 48% increase in insulin content and c-peptide secretion respectively compared with nicotinamide alone. |
2005-09-22 |
2023-08-12 |
mouse |
| L Bai, G Meredith, B E Tuc. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079260. |
it is concluded that both glp-1 and exendin-4 enhance the level of expression of insulin in glucose-responsive insulin-producing cells derived from the r1 mesc line. |
2005-09-22 |
2023-08-12 |
mouse |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
glucagon-like peptide-1 (glp-1) is a peptide hormone secreted from the enteroendocrine l-cells of the gut and which acts primarily to potentiate the effects of glucose on insulin secretion from pancreatic beta-cells. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
previous studies on the mechanisms whereby glp-1 regulates insulin gene transcription have focused on the rat insulin promoter. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
the aim of this study was to determine whether the human insulin promoter was also responsive to glp-1, and if so to investigate the possible role of camp-responsive elements (cres) that lie upstream (cre1 and cre2) and downstream (cre3 and cre4) of the transcription start site. |
2005-09-22 |
2023-08-12 |
human |
| Colin W Hay, Elaine M Sinclair, Giovanna Bermano, Elaine Durward, Mohammad Tadayyon, Kevin Dochert. Glucagon-like peptide-1 stimulates human insulin promoter activity in part through cAMP-responsive elements that lie upstream and downstream of the transcription start site. The Journal of endocrinology. vol 186. issue 2. 2005-09-22. PMID:16079261. |
glp-1 was found to stimulate the human insulin promoter, albeit to a lesser degree than the rat insulin promoter. |
2005-09-22 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
initially more rapid small intestinal glucose delivery increases plasma insulin, gip, and glp-1 but does not improve overall glycemia in healthy subjects. |
2005-09-21 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
the latter is also dependent on stimulation of insulin secretion by glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1). |
2005-09-21 |
2023-08-12 |
human |
| Reawika Chaikomin, Selena Doran, Karen L Jones, Christine Feinle-Bisset, Deirdre O'Donovan, Christopher K Rayner, Michael Horowit. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. American journal of physiology. Endocrinology and metabolism. vol 289. issue 3. 2005-09-21. PMID:15886226. |
between t = 0 and 75 min, plasma insulin, gip, and glp-1 were higher with the variable infusion. |
2005-09-21 |
2023-08-12 |
human |
| J F Gautier, S Fetita, E Sobngwi, C Salaün-Marti. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & metabolism. vol 31. issue 3 Pt 1. 2005-09-21. PMID:16142014. |
in humans, the incretin effect is mainly caused by two peptide hormones, glucose-dependent insulin releasing polypeptide gip, and glucagon-like peptide-1 glp-1. |
2005-09-21 |
2023-08-12 |
Not clear |
| J F Gautier, S Fetita, E Sobngwi, C Salaün-Marti. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & metabolism. vol 31. issue 3 Pt 1. 2005-09-21. PMID:16142014. |
in addition to its effects on insulin secretion, glp-1 exerts other significant actions, including stimulation of insulin biosynthesis, inhibition of glucagon secretion, inhibition of gastric emptying and acid secretion, reduction of food intake, and trophic effects on the pancreas. |
2005-09-21 |
2023-08-12 |
Not clear |
| Guoxin Kang, Oleg G Chepurny, Michael J Rindler, Leon Collis, Zina Chepurny, Wen-Hong Li, Mark Harbeck, Michael W Roe, George G Hol. A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells. The Journal of physiology. vol 566. issue Pt 1. 2005-09-16. PMID:15860526. |
we propose that second messenger coincidence detection of this type may explain how glp-1 interacts with beta cell glucose metabolism to stimulate insulin secretion. |
2005-09-16 |
2023-08-12 |
mouse |